Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

• Status: Completed
• Trial end date: 2017-10-30
• Target enrollment: 0
• Participant gender: All

Summary

Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• Treatments: Budesonide; Poractant alfa

Criteria

Inclusion Criteria:

• Clinical diagnosis of respiratory distress syndrome

Exclusion Criteria:

• pneumothorax

• surgical disease

• major congenical defects